Go Pro
NASDAQ:RCEL

Avita Medical Q2 2026 Earnings Report

Avita Medical logo
$4.06 -0.35 (-7.94%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$4.07 +0.01 (+0.12%)
As of 07/10/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Avita Medical EPS Results

Actual EPS
N/A
Consensus EPS
-$0.29
Beat/Miss
N/A
One Year Ago EPS
N/A

Avita Medical Revenue Results

Actual Revenue
N/A
Expected Revenue
$20.25 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Avita Medical Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
Thursday, August 6, 2026
Conference Call Time
4:30PM ET

Conference Call Resources

Avita Medical Earnings Headlines

Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
See More Avita Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Avita Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avita Medical and other key companies, straight to your email.

About Avita Medical

Avita Medical (NASDAQ:RCEL), Inc. (NASDAQ: RCEL) is a regenerative medicine company focused on the development and commercialization of cell‐based therapies for acute and chronic wounds. Its flagship technology, the ReCell® Autologous Cell Harvesting Device, enables clinicians to create a suspension of a patient’s own skin cells at the point of care. The system is designed to accelerate wound healing, minimize donor‐site requirements and reduce scarring for patients suffering from burns, traumatic wounds and a variety of surgical and reconstructive procedures.

Founded in 2009 and headquartered in Carlsbad, California, Avita Medical has secured regulatory clearances in key markets, including CE mark approval in the European Union and 510(k) clearance from the U.S. Food and Drug Administration for acute thermal burn wounds. The company has since expanded its clinical indications and market access efforts into regions such as Australia, China and other parts of Asia. Avita collaborates with leading burn centers, academic institutions and investigator‐initiated trials to explore additional applications—ranging from chronic diabetic ulcers to vitiligo and hair restoration.

Under the leadership of President and Chief Executive Officer Michael Perry, Avita Medical has emphasized the integration of its proprietary cell‐harvesting technology into standard burn and wound care protocols. The company maintains a global commercial infrastructure to support physician training, clinical research, and post‐market surveillance. Its strategic priorities include broadening clinical adoption of ReCell, pursuing new regulatory approvals and fostering partnerships to extend its regenerative platform into adjacent markets.

View Avita Medical Profile